Ascendis Pharma As Stock Performance
| ASND Stock | USD 224.19 2.16 0.97% |
On a scale of 0 to 100, Ascendis Pharma holds a performance score of 6. The firm shows a Beta (market volatility) of -0.41, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ascendis Pharma are expected to decrease at a much lower rate. During the bear market, Ascendis Pharma is likely to outperform the market. Please check Ascendis Pharma's value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to make a quick decision on whether Ascendis Pharma's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ascendis Pharma AS are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Ascendis Pharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.05) | Five Day Return 0.78 | Year To Date Return 4.1 | Ten Year Return 1.1 K | All Time Return 1.1 K |
1 | Ascendis Announces Extension of FDA Review Period for TransCon CNP for Children with Achondroplasia | 11/25/2025 |
2 | Ascendis Pharma Grants Employee Warrants to Strengthen Market Position - TipRanks | 12/10/2025 |
3 | Wells Fargo Maintains Ascendis Pharma AS With Buy Rating, Maintains Target Price 297 - | 01/07/2026 |
4 | Assessing Ascendis Pharma Valuation After Positive COACH Trial Growth And Proportionality Results | 01/16/2026 |
5 | Best Growth Stocks To Consider January 21st | 01/21/2026 |
6 | Assessing Ascendis Pharma Valuation After Strong Recent Share Price And Revenue Growth | 01/23/2026 |
7 | Ascendis Pharma Jumps 7.5 percent on RumorsIs a European Mega Deal in the Works - Smartkarma | 01/26/2026 |
8 | BofA Reiterates Buy Rating on Ascendis Pharma While Wells Fargo Analyst Raises PT | 01/29/2026 |
9 | Top Growth Stocks To Add to Your Watchlist January 30th | 01/30/2026 |
10 | Growth Stocks To Watch Now February 3rd | 02/04/2026 |
11 | Has Ascendis Pharma Share Price Outpaced Its Fundamentals After Pipeline Progress News | 02/06/2026 |
12 | Promising Growth Stocks To Consider February 8th | 02/09/2026 |
| Begin Period Cash Flow | 392.2 M | |
| Total Cashflows From Investing Activities | 6.9 M |
Ascendis Pharma Relative Risk vs. Return Landscape
If you would invest 19,922 in Ascendis Pharma AS on November 12, 2025 and sell it today you would earn a total of 2,497 from holding Ascendis Pharma AS or generate 12.53% return on investment over 90 days. Ascendis Pharma AS is currently generating 0.2284% in daily expected returns and assumes 2.6534% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Ascendis, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ascendis Pharma Target Price Odds to finish over Current Price
The tendency of Ascendis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 224.19 | 90 days | 224.19 | about 9.19 |
Based on a normal probability distribution, the odds of Ascendis Pharma to move above the current price in 90 days from now is about 9.19 (This Ascendis Pharma AS probability density function shows the probability of Ascendis Stock to fall within a particular range of prices over 90 days) .
Ascendis Pharma Price Density |
| Price |
Predictive Modules for Ascendis Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ascendis Pharma AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ascendis Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ascendis Pharma is not an exception. The market had few large corrections towards the Ascendis Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ascendis Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ascendis Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | -0.41 | |
σ | Overall volatility | 9.39 | |
Ir | Information ratio | 0.01 |
Ascendis Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ascendis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ascendis Pharma AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 561.21 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Promising Growth Stocks To Consider February 8th |
Ascendis Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ascendis Stock often depends not only on the future outlook of the current and potential Ascendis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ascendis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 57.9 M | |
| Cash And Short Term Investments | 559.5 M |
Ascendis Pharma Fundamentals Growth
Ascendis Stock prices reflect investors' perceptions of the future prospects and financial health of Ascendis Pharma, and Ascendis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascendis Stock performance.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.0769 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 13.91 B | ||||
| Shares Outstanding | 61.1 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 20.99 X | ||||
| Revenue | 363.64 M | ||||
| Gross Profit | 561.21 M | ||||
| EBITDA | (290.02 M) | ||||
| Net Income | (378.08 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 856.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (3.37) X | ||||
| Cash Flow From Operations | (306.2 M) | ||||
| Earnings Per Share | (4.52) X | ||||
| Market Capitalization | 13.57 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 153 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
About Ascendis Pharma Performance
By analyzing Ascendis Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascendis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascendis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascendis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.8 K | 4.4 K | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (1.18) | (1.24) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | 3.22 | 3.38 |
Things to note about Ascendis Pharma AS performance evaluation
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 561.21 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Promising Growth Stocks To Consider February 8th |
- Analyzing Ascendis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascendis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascendis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascendis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascendis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascendis Pharma's stock. These opinions can provide insight into Ascendis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |